| Cardiovascular Function and Risk Factors | Lifetime | 125 | GB 8 | 99.74 |
| Diabetes Treatment and Management | Lifetime | 73 | GB 9 | 99.63 |
| Heart Failure Treatment and Management | Lifetime | 66 | GB 3 | 99.73 |
| Potassium and Related Disorders | Lifetime | 17 | GB 2 | 99.51 |
| Hormonal Regulation and Hypertension | Lifetime | 134 | GB 16 | 99.24 |
| Electrolyte and hormonal disorders | Lifetime | 84 | GB 5 | 98.84 |
| COVID-19 Clinical Research Studies | Lifetime | 365 | GB 39 | 98.46 |
| Cardiac pacing and defibrillation studies | Lifetime | 196 | GB 9 | 99.33 |
| COVID-19 and healthcare impacts | Lifetime | 199 | GB 47 | 96.84 |
| Blood Pressure and Hypertension Studies | Lifetime | 463 | GB 43 | 98.67 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 364 | GB 23 | 98.30 |
| Pancreatic function and diabetes | Lifetime | 859 | GB 90 | 97.81 |
| Diabetes Management and Research | Lifetime | 870 | GB 96 | 97.31 |
| Medication Adherence and Compliance | Lifetime | 304 | GB 20 | 95.79 |
| Cardiovascular Health and Risk Factors | Lifetime | 971 | GB 62 | 89.40 |
| Heart rate and cardiovascular health | Lifetime | 213 | GB 19 | 87.36 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 10 | GB 2 | 99.95 |
| Heart Failure Treatment and Management | 2021-2025 | 4 | GB 1 | 99.96 |
| Diabetes Treatment and Management | 2021-2025 | 8 | GB 1 | 99.93 |
| Potassium and Related Disorders | 2021-2025 | 1 | GB 1 | 99.89 |
| Hormonal Regulation and Hypertension | 2021-2025 | 4 | GB 1 | 99.85 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 16 | GB 3 | 99.57 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 21 | GB 2 | 99.64 |
| Pancreatic function and diabetes | 2021-2025 | 28 | GB 3 | 99.17 |
| Electrolyte and hormonal disorders | 2021-2025 | 7 | GB 1 | 98.34 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 50 | GB 6 | 98.41 |
| Diabetes Management and Research | 2021-2025 | 132 | GB 15 | 98.06 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 287 | GB 47 | 97.12 |
| COVID-19 and healthcare impacts | 2021-2025 | 379 | GB 85 | 93.96 |
| Medication Adherence and Compliance | 2021-2025 | 61 | GB 2 | 94.47 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 177 | GB 15 | 95.74 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 570 | GB 23 | 90.51 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 890 | GB 53 | 90.02 |
| Dialysis and Renal Disease Management | 2021-2025 | 856 | GB 60 | 87.38 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 541 | GB 22 | 83.44 |
| Influenza Virus Research Studies | 2021-2025 | 981 | GB 65 | 84.56 |
| Cardiac Health and Mental Health | 2021-2025 | 918 | GB 62 | 81.49 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 997 | GB 89 | 81.94 |
| Heart rate and cardiovascular health | 2021-2025 | 51 | GB 2 | 72.51 |
| Healthcare cost, quality, practices | 2021-2025 | 829 | GB 109 | 71.66 |
| Ion Transport and Channel Regulation | 2021-2025 | 307 | GB 6 | 71.88 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 626 | GB 24 | 63.40 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 842 | GB 69 | 53.21 |
| Renal function and acid-base balance | 2021-2025 | 812 | GB 35 | 52.31 |
| Apelin-related biomedical research | 2021-2025 | 587 | GB 17 | 43.88 |
